Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Welcome and Introduction to Vi3C

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement

Jul

13

Today In Oncology

ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers

FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer

Long-Term Overall Survival With Addition of SBRT to Abiraterone Acetate and ADT in Oligometastatic Castration-Resistant Prostate Cancer

FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications

FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer

Advertisement

© 2026 HSP News Service, L.L.C.